Healthcare-focused SPAC NorthView Acquisition prices $165 million IPO

NorthView Acquisition, a blank check company targeting small cap healthcare businesses in North America, Europe, and APAC, raised $165 million by offering 16.5 million units at $10. The company offered 1.5 million more units than anticipated. It originally planned to offer 18 million units before lowering the deal size earlier this month. Each unit consists of one share of common stock, one right to receive one-tenth of a share upon the completion of an initial business combination, and one-half of a warrant, exercisable at $11.50.

The company was formed by CEO and Director Jack Stover, whose former roles include serving as CEO of Interpace Biosciences and Antares Pharma, and CFO and Director Fred Knechtel, who previously served as the CFO of Interpace and GENEWIZ. The company plans to target small cap businesses domiciled in North America, Europe and/or the APAC regions that are developing assets in the biopharmaceutical, medical technology/medical device, and diagnostics spaces.

NorthView Acquisition plans to list on the Nasdaq under the symbol NVACU. I-Bankers Securities acted as sole bookrunner on the deal.